Short answer
OptimizeRx Corp (OPRX) filed an 8-K current report with the SEC on June 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Theresa Greco departs as Chief Commercial Officer effective June 15, 2026, creating a commercial leadership transition.
OptimizeRx Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Theresa Greco departs as Chief Commercial Officer effective June 15, 2026, creating a commercial leadership transition
- $380,000 annual salary continuation for 12 months plus $209,000 one-time bonus target payment
- Twelve months of COBRA premium reimbursement and continued equity vesting during advisory term
- Advisory services continue through June 15, 2027, preserving access to Greco’s commercial expertise
- 12-month non-compete and non-solicitation restrictions limit immediate competitive and employee/customer poaching risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OptimizeRx Corp 8-K filings
Get the next OPRX 8-K as it lands
Follow OPRX for push alerts, or ask the research agent what this filing means.